IR
HAE icon

Invictus RG’s Haemonetics HAE Stock Holding History

Invictus RG’s Portfolio HAE Stock Details HAE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2018
Q4 		– Sell
-2,605
Closed -$298K – 66
2018
Q3 		$298K Sell
2,605
-3,611
-58% -$374K 0.23% 127
2018
Q2 		$557K Buy
+6,216
New +$525K 0.47% 31
2018
Q1 		– Sell
-5,605
Closed -$326K – 284
2017
Q4 		$326K Buy
5,605
+4,989
+810% +$263K 0.35% 129
2017
Q3 		$28K Sell
616
-6,921
-92% -$288K 0.03% 401
2017
Q2 		$298K Buy
+7,537
New +$310K 0.22% 184
2017
Q1 		– Sell
-10,640
Closed -$428K – 746
2016
Q4 		$428K Buy
10,640
+9,709
+1,043% +$366K 0.29% 108
2016
Q3 		$34K Sell
931
-2,388
-72% -$82K 0.03% 511
2016
Q2 		$96K Sell
3,319
-755
-19% -$22.8K 0.1% 301
2016
Q1 		$143K Buy
4,074
+681
+20% +$22K 0.17% 228
2015
Q4 		$109K Buy
+3,393
New +$110K 0.1% 294

Other funds holding HAE

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
JSP
Jackson Square Partners Larkspur, California $247M AUM 20.29% 1-Year Est. Return
Neuberger Berman Group
Neuberger Berman Group New York $150B AUM 40.08% 1-Year Est. Return
Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $717B AUM 35.42% 1-Year Est. Return
HM
HealthCor Management New York $109M AUM 10.64% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return

Invictus RG's HAE Position: Q4 2018 in Review

Invictus RG sold out of Haemonetics (HAE) in Q4 2018, closing a stake of 2,605 shares — an estimated $298K sold.

Invictus RG first reported a position in HAE in Q4 2015 and held it in 10 quarters. The position peaked at $557K in Q2 2018. 279 funds tracked by Wall St. Rank hold HAE as of Q4 2018.

  • Invictus RG reported no remaining Haemonetics position as of Q4 2018 after selling out during the quarter.
  • Invictus RG sold 2,605 Haemonetics shares in Q4 2018, an estimated $298K.
  • Invictus RG first reported a position in Haemonetics in Q4 2015 and held it in 10 quarters.
  • Invictus RG's Haemonetics position peaked at $557K in Q2 2018.
  • 279 funds tracked by Wall St. Rank held Haemonetics as of Q4 2018.

Based on Invictus RG's 13F filing for Q4 2018, filed 13 Feb 2019.